fbpx

molecules of the month

compound 10

tumor specific prodrug of TGFβR inhibitor

QW dosing, improved tumor-to-heart ratio

BMS-986260 prodrug w/ self-immolative link.

Journal of Medicinal Chemistry

Bristol Myers Squibb, Princeton, NJ

Chemical structure of "compound 10" BMS TGFβR inhibitor prodrug
1 min read

The BMS TGFβR inhibitor prodrug, “compound 10,” demonstrates antitumor efficacy comparable to the parent compound (BMS-986260) in a syngeneic model with once-weekly dosing, while reducing the systemic exposure of BMS-986260. Reducing the systemic exposure of a TGFβR inhibitor is important due to previously observed mechanism-based cardiac toxicity. This prodrug is preferentially cleaved by proteases overexpressed in tumors, and results in a prolonged, favorable tumor-to-heart ratio of the active drug in distribution studies. This is an interesting proof-of-concept for tumor-targeted prodrugs as an approach to improving the therapeutic index of cancer drugs. It is especially interesting in the immune-oncology setting where the initiation of anticancer activity in a tumor may lead to an abscopal effect and broader systemic responses due to…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: